The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of TRIAPEX LABORATORIES CO., LTD. 江蘇鼎泰藥物研究(集團)股份有限公司 (A joint stock company incorporated in the People's Republic of C ...

Group 1: Fund Performance - Madison Mid Cap Fund (Class Y) returned 5.2% in Q2 2025, underperforming the Russell Midcap Index which increased by 8.5% [1] - The fund's top five holdings were highlighted, indicating its best investment picks for 2025 [1] Group 2: Medpace Holdings, Inc. Overview - Medpace Holdings, Inc. (NASDAQ:MEDP) is a clinical research-based drug and medical device development services provider [2] - The stock of Medpace Holdings, Inc. had a one-month return of 8.26% and a 52-week gain of 37.25%, closing at $501.94 per share with a market capitalization of $14.101 billion on September 18, 2025 [2] Group 3: Investment Insights on Medpace Holdings, Inc. - Madison Mid Cap Fund added Medpace Holdings, Inc. as a new investment in Q2 2025, emphasizing its focus on providing clinical trial services to small biotech companies [3] - The company, led by founder Dr. August Troendle, has a differentiated expertise in oncology and metabolic disorders, with only a ~5% share of the addressable market, indicating significant growth potential [3] - Medpace Holdings, Inc. reported revenue of $603.3 million in Q2 2025, reflecting a year-over-year increase of 14.2% [4]